Blog.
Long-form posts on biopharma AI, CMC, regulatory cross-reference, and engineering. Every post is signed by an engineer or scientist who actually built or used the thing.
How to set up a global biopharma intelligence pipeline in 30 minutes
A practical 30-minute setup for a daily biopharma intelligence pipeline — 7+ sources, cross-source dedup, AI summaries, push to Slack / WeChat / email.
Inscinstech's CMC knowledge base v2.2: What's in it and why it matters
82+ curated CMC entries, FDA review document distillations, and process precedent data — what is actually inside AI4CMC v2.2 and how it powers the inscinstech.ai agents.
FDA vs NMPA vs EMA: How they differ on mAb biosimilar guidance in 2026
A side-by-side look at how the FDA, NMPA, and EMA handle mAb biosimilar guidance in 2026 — where they converge, where they still diverge, and what it means for your filing strategy.
The state of open-source Agent frameworks in 2026: Hermes, LangGraph, and what we picked
We evaluated 8 Agent frameworks before picking the one we run inCore on. Here are the trade-offs we considered, what we chose, and why we forked it.
Why most molecules fail CMC — and 8 things you can predict at design time
Most molecule failures in CMC are predictable from the sequence. Here are 8 dimensions you can score in 30 seconds — before you start a tank.